A roundtable discussion, moderated by Laurence Albiges, MD, PhD, discussed the risk stratification and management of metastatic non-clear cell renal cell carcinoma (nccRCC), along with recent advancements in targeted therapies and immuno-agents, treatment sequencing and combination approaches, and adjuvant therapy options. Dr. Albiges was joined by Renée Maria Saliby, MD, MSc; Tian Zhang, MD; and Shahla Bari, MD. ...
nccRCC
Advertisement
CEUS for the assessment of nccRCC can provide a more sensitive alternative to conventional ultrasound imaging.
The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo.
The panel focuses on CN, oligometastatic disease treatment, and advancements in systemic therapies over the past few decades.
The panel explores our understanding of nccRCC, including classification, molecular distinctions, and prognostic criteria.
A recent study that sought to characterize rare kidney tumors has identified novel biomarkers in nccRCC subtypes.
Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.
Dr. Albiges comments on the latest data from the nccRCC trial KEYNOTE-B61, including an extended follow-up analysis.
The study sought to better understand the effects of first-line systemic therapy in metastatic ChRCC.
Dr. Nguyen shares an ongoing study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma.
Dr. Doshi and colleagues designed an analysis of patients with metastatic ChRCC to better understand first-line therapy.
Advertisement
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
![PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2024/06/122-GUOnc_YouTube_Sartor_1280x720.jpg)
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Advertisement
Advertisement
Latest News
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
Researchers focused on the economic impact of disparities related to insurance coverage.
ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth
The group discusses how blocking ACSS2 may affect immune cells in the tumor microenvironment. 